We found the alterations of branched-chain amino acid-related metabolomes in the plasma of both HER2-positive and HER2-negative breast cancer patients 2 weeks after completion of doxorubicin treatment, which was consistent with our previous study in rats [16]. The gene discussed is ERBB2; the disease is breast carcinoma.